89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024 [Yahoo! Finance]
89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants